NASDAQ : LXRX

Lexicon Pharmaceuticals, Inc.

$2.29 USD

-$0.01 (-0.43%)

Volume
1.68M
Average Volume
3.38M
Market Capitalization
$1.02B
P/E Ratio
-32.07
Dividend Yield
0.00%
Price Target
$6.00
Year High
$2.68
Year Low
$1.00
Day High
Day Low
Payout Ratio
$0.00
Current Ratio
$18.79
Company Overview

NASDAQ

Michael S. Exton

Biotechnology

Healthcare

LXRX

81

US

USD

281 863 3000

528872302

0001062822

Liquidity Metrics

0.28

18.79

18.77

3.85

0.00

Sales & Valuation

$49.8M

14.61

4.52

-26.21

-0.10

Profitability

-$0.14

-$50.34M

-37.46%

-37.46%

-18.64%

-9.71%

P/E Metrics

-32.07

-0.12

-0.12

Analyst Price Target & Rating

$6.00

$6.00

$6.00

Strong Sell

1/5

14 Analysts

-61.83%

Financial Health Scores

-0.44

4/9

$176.13M

$268.82M

$65.96M

-$18M

Key Metrics (TTM)

$1.04B

14.89

-59.45

18.79

-18.64%

-9.30%

-2.85%

-3.81%

-1475 days

Company Executives
Name Title
Brian T. Crum Senior Vice President, General Counsel & Secretary
Rachel Yap Martens Senior VP of Partnerships & Corporate Strategy
Wendy E. McDermott Senior Vice President of Human Resources
Kristen L. Alexander Vice President of Finance & Accounting
Craig Granowitz Senior Vice President & Chief Medical Officer
Michael Exton Chief Executive Officer & Director
Suma Gopinathan Senior Vice President of Discovery
Scott Coiante Senior Vice President & Chief Financial Officer
Lisa DeFrancesco Senior Vice President of Investor Relations & Corporate Communications
Poll Results

No votes yet today — be the first to share your view!

About Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Stock

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the end-to-end process of identifying, advancing, and bringing to market novel therapeutic compounds. Its development pipeline includes orally administered small molecule drug candidates such as Sotagliflozin, which has successfully concluded Phase III clinical studies for treating both heart failure and type 1 diabetes, and LX9211, currently undergoing Phase II clinical development for neuropathic pain. The firm maintains important strategic collaborations and licensing arrangements with pharmaceutical industry leaders, including Bristol-Myers Squibb Company and Genentech, Inc. Established in 1995, Lexicon Pharmaceuticals, Inc. is based in The Woodlands, Texas. ...

Here's Why You Should Add LXRX Stock to Your Portfolio Now

2026-06-22 11:41:17

Lexicon advances sotagliflozin into new indications while its obesity and pain programs progress, setting the stage for multiple pipeline milestones.

Lexicon Pharmaceuticals vs. Pfizer: Which Drugmaker Stock Is a Better Buy in 2026?

2026-06-11 09:45:55

One company posts rapid revenue growth but remains unprofitable, while the other boasts global scale and steady cash flow. See how their fundamentals stack up.

Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions

2026-06-03 08:00:00

Presentations highlight consistent A1c reductions with sotagliflozin in type 1 diabetes and pharmacokinetics of pilavapadin across renal function groups Presentations highlight consistent A1c reductions with sotagliflozin in type 1 diabetes and pharmacokinetics of pilavapadin across renal function groups

Lexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference

2026-05-28 08:30:00

THE WOODLANDS, Texas, May 28, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 4, 2026 at 2:00 p.m. ET in New York City.

Lexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference

2026-05-12 08:30:00

THE WOODLANDS, Texas, May 12, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the 4th Annual H.C. Wainwright BioConnect Investor Conference, taking place at the Nasdaq World Headquarters in New York City, on May 19, 2026.

Lexicon Pharmaceuticals Q1 Earnings Call Highlights

2026-05-08 16:12:11

Lexicon Pharmaceuticals NASDAQ: LXRX executives highlighted progress across late-stage regulatory programs and efforts to bolster the company's financial position during the company's first-quarter 2026 earnings call on May 7.

Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2026 Earnings Call Transcript

2026-05-07 17:11:13

Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2026 Earnings Call Transcript

Lexicon Pharmaceuticals (LXRX) Reports Break-Even Earnings for Q1

2026-05-07 09:55:55

Lexicon Pharmaceuticals (LXRX) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to a loss of $0.07 per share a year ago.

Frequently Asked Questions

What is the current Lexicon Pharmaceuticals, Inc. (LXRX) stock price?

Lexicon Pharmaceuticals, Inc.(NASDAQ:LXRX) stock price is $2.29 in the last trading session. During the trading session, LXRX stock reached the peak price of $2.68 while $1 was the lowest point it dropped to. The percentage change in LXRX stock occurred in the recent session was --0.43% while the dollar amount for the price change in LXRX stock was -$0.01.

LXRX's industry and sector of operation?

The NASDAQ listed LXRX is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of LXRX?

Brian T. Crum | Senior Vice President, General Counsel & Secretary
Rachel Yap Martens | Senior VP of Partnerships & Corporate Strategy
Wendy E. McDermott | Senior Vice President of Human Resources
Kristen L. Alexander | Vice President of Finance & Accounting
Craig Granowitz | Senior Vice President & Chief Medical Officer

How many employees does LXRX have?

Number of LXRX employees currently stands at 81. LXRX operates from 2445 Technology Forest Boulevard, The Woodlands, TX 77381, US.

Link for LXRX official website?

Official Website of LXRX is: https://www.lexpharma.com

How do I contact LXRX?

LXRX could be contacted at phone #281 863 3000 and can also be accessed through its website. LXRX operates from 2445 Technology Forest Boulevard, The Woodlands, TX 77381, US.

How many shares of LXRX are traded daily?

The average number of LXRX shares traded daily for last 3 months was 3.38M.

What is the market cap of LXRX currently?

The market value of LXRX currently stands at $1.02B with its latest stock price at $2.29